Skip to Content
Merck
All Photos(1)

Documents

1292303

USP

Glimepiride

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Glimepiride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H34N4O5S
CAS Number:
93479-97-1
Molecular Weight:
490.62
MDL number:
MFCD00878417
UNSPSC Code:
41116107
PubChem Substance ID:
329749940
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

glimepiride

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

Gene Information

human ... ABCC8(6833) , KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Glimepiride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Glimepiride Tablets
  • Pioglitazone and Glimepiride Tablets

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1292325

Glimepiride Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0000516

Glimepiride for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000515

Glimepiride, European Pharmacopoeia (EP) Reference Standard

1292314

Glimepiride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1292336

Glimepiride Related Compound C, United States Pharmacopeia (USP) Reference Standard

1292347

Glimepiride Related Compound D, United States Pharmacopeia (USP) Reference Standard

Y0001742

Glimepiride for impurity A identification, European Pharmacopoeia (EP) Reference Standard

PHR1727

Glimepiride Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1725

Glimepiride cis-Isomer (Glimepiride Related Compound A), Pharmaceutical Secondary Standard; Certified Reference Material

BP1144

Glimepiride, British Pharmacopoeia (BP) Reference Standard

PHR1726

Glimepiride Sulfonamide, pharmaceutical secondary standard, certified reference material

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Pioglitazone hydrochloride United States Pharmacopeia (USP) Reference Standard

USP

1539905

Pioglitazone hydrochloride

Metformin hydrochloride United States Pharmacopeia (USP) Reference Standard

USP

1396309

Metformin hydrochloride

J Rosenstock et al.
Diabetes care, 19(11), 1194-1199 (1996-11-01)
To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM. Of the previously treated NIDDM patients, 416 entered this multicenter
T F Veneman et al.
The Netherlands journal of medicine, 52(5), 179-186 (1998-07-04)
Disturbances in insulin secretion and insulin action are both involved in the pathophysiology of type 2 (or non-insulin-dependent) diabetes mellitus. The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and
Mary T Korytkowski
Pharmacotherapy, 24(5), 606-620 (2004-05-28)
Sulfonylureas, which have evolved through two generations since their introduction nearly 50 years ago, remain the most frequently prescribed oral agents for treatment of patients with type 2 diabetes mellitus. Glyburide, glipizide, and glimepiride, the newest sulfonylureas, are as effective
M Nauck et al.
Diabetes, obesity & metabolism, 15(3), 204-212 (2012-09-19)
To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes. In the 26-week the Liraglutide Effect and Action in Diabetes
Massimo Massi-Benedetti
Clinical therapeutics, 25(3), 799-816 (2003-07-11)
Sulfonylureas (SUs) have been used for many years as first-line therapy for patients with type 2 diabetes mellitus whose blood glucose levels have not been effectively controlled by diet and exercise alone. Glimepiride is a once-daily SU that was introduced
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service